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Abstract: Lysophosphatidic acid (LPA), a naturally occurring glycerophospholipid, can 
evoke various biological responses, including cell migration, proliferation and survival, via 
activation of G protein-coupled receptors (GPCRs). However, the role of LPA receptors 
and details of LPA signaling in migration are largely unexplored. In this study we detect 
the expression of LPA1 and LPA3 receptors in rat aortic smooth muscle cells (RASMCs). 
LPA stimulated RASMCs migration in a dose-dependent manner and induced the 
phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) and extracellular 
signal-regulated kinase (ERK). LPA-induced cell migration was significantly inhibited by 
specific LPA1/LPA3-receptor antagonist Dioctylglycerol pyrophosphate (8:0) (DGPP8.0) 
at higher concentration. Migration of cells toward LPA was partially, but significantly, 
reduced in the presence of SB-203580, a p38 MAPK inhibitor, but not PD98059, an ERK 
inhibitor. In addition, pertussis toxin (PTX), a Gi protein inhibitor, induced an inhibitory 
effect on p38 MAPK,ERK phosphorylation and RASMCs migration. These data suggest 
that LPA-induced migration is mediated through the Gi-protein-coupled LPA1 receptor 
involving activation of a PTX-sensitive Gi / p38MAPK pathway. 
Keywords: lysophosphatidic acid; receptor; vascular smooth muscle cell; migration; p38 
mitogen-activated protein kinase 
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1. Introduction 
 
Lysophosphatidic acid (LPA) is a member of the lysophospholipid class of phospholipids that is an 
intermediate in phospholipid metabolism [1]. In addition to being a key intermediate in de novo lipid 
synthesis, LPA is also an important intercellular messenger, which can act as either an autocrine or 
paracrine mediator. Originally reported to be the primary phospholipid growth factor in mammalian 
serum [2,3], it is now known to be a mediator of diverse cellular processes, such as migration [4-6], 
proliferation and cell survival [7,8], aggregation of platelets [9,10], smooth-muscle contraction [11,12], 
cytoskeletal reorganization [13-14], myelination [15,16], neurogenesis [17,18] and neurotransmitter 
release [19,20]. 
LPA elicits these cellular effects on most cell types through the activation of its specific G 
protein–coupled receptors (GPCRs). At least six LPA-specific mammalian GPCRs, LPA1-6, have 
been identified to date. Among the six LPA receptors, LPA1 [21], LPA2 [22] and LPA3 [23] are 
members of the endothelial differentiation gene (EDG) family , share about 50% amino acid sequence 
identities. The other three LPA receptors LPA4/p2y9 [24], LPA5/GPR92 [25,26],LPA6/GPR87 [27], 
which show small similarities with the Edg family GPCRs, were recently identified and comparatively 
less is known about these receptors. LPA1 is the receptor with the widest distribution, the expression 
of LPA2 and LPA3 is somewhat more restricted, whereas LPA4 is expressed only in the ovary [24], 
LPA5 is mainly expressed in the lymphocyte compartment of the gastrointestinal tract, sensory dorsal 
root ganglia as well as embryonic stem cells [25,26], LPA6 was expressed in placenta, ovary, testis, 
prostate, brain, and skeletal muscle [27]. 
When an agonist interacts with a specific GPCR, its associated G-protein is activated and induces a 
specific intracellular pathway that leads to the final cellular response. At least three different 
heterotrimeric G-proteins have been associated with the actions of LPA in various cell types: Gi/o, 
Gq/11, and G12/13 [28,29]. 
The migration of vascular smooth muscle cells (VSMCs) is believed to play a major role in the 
pathogenesis of atherosclerosis and is the main cause of restenosis after balloon angioplasty. 
Elucidation of the mediators and knowledge of their mode of action may provide useful information 
for the development of therapeutic treatments for these diseases [30]. In VSMCs, LPA has been shown 
to stimulate migration [31]
 and proliferation [32]. Results derived from LPA receptor knockout mice 
illustrate that LPA1
–/–2
–/– SMCs exhibit decreased migration in response to LPA, whereas LPA1
–/– 
SMCs exhibit enhanced migration in response to upregulation of the LPA3 receptor [33].Damirin A et 
al [34] demonstrated that LPA1 receptors are involved in the LDL-induced migration of human 
coronary artery smooth muscle cells.
 However, the roles of LPA receptors in LPA-stimulated VSMCs 
migration are far from been elucidated
 in detail. MAPKs are believed to be associated with the 
migration and proliferation of VSMCs [35,36], but which subfamily of MAPKs is involved in VSMCs 
remains controversial. The present study was designed to determine the involvement of LPA receptors 
in LPA-stimulated migration of VSMC and the signaling pathways involved. 
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2. Results and Discussion 
 
2.1. RASMCs Migration toward LPA 
 
In order to confirm that LPA was able to induced RASMCs migration in our model, we performed a 
cellular migration assay. RASMCs (1x10
5 cells) were added to the upper wells of the Boyden chamber 
containing LPA (0–25 μM) in the lower chamber. Cells were incubated for 6 h to allow to migration. 
Results show that cells were induced by LPA to migrate to the lower well in a dose-dependent manner. 
The greatest number of migrating cells occurred at 10 μM LPA. The number of migrating cells 
decreased at higher LPA concentrations (Figure 1).   
 
Figure 1. LPA-induced migration of RASMCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RASMCs were stimulated with the indicated concentrations of LPA and migration 
was determined using the Boyden chamber assay. Values are means ±S.E.M n =3. 
*P＜0.01 vs. control (0μM LPA). 
2.2. LPA Receptor Expression 
 
As we have demonstrated that LPA can induce RASMCs migration, it was then essential to 
determine which LPA receptor may be responsible. Up to date, six receptors have been described, 
whereas LPA4-6 are not expressed in vascular tissue. Therefore we performed Semi-quantitative 
RT-PCR analysis to determine mRNA expression levels of the LPA receptors(LPA1-3) in RASMCs. 
Consistant with previous results [37], LPA1 and LPA3 were expressed in RASMCs, whereas LPA2 
expression could not be detected (Figure 2).   
 
2.3. LPA-Induced Migration in RASMCs Is Mediated by LPA1 Receptor 
 
To characterize the receptors involved in LPA-induced migration of RASMCs, cells were treated 
with varying concentrations of the LPA1 and LPA3 antagonist, DGPP8:0, and LPA3 agonist, OMPT Int. J. Mol. Sci. 2009, 10                 
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in the presence or absence of LPA (10 μM). The migration response to LPA was significantly inhibited 
by DGPP8:0 at 10 μM and was almost completely inhibited at 50μM. However, low concentrations of 
DGPP (0.1-1μM) and all concentrations of OMPT (up to 50μ M) had little effect on LPA-induced 
migration (Figure 3). DGPP has been shown to block LPA3 and LPA1 receptors with a Ki of 106 nM 
and 6.6 μM, respectively [38]. Therefore, these data suggest that LPA induced RASMCs migration 
may be mediated through the LPA1 receptor. 
 
Figure 2. LPA receptor expression in RASMCs. Total RNA was isolated and RT-PCR was 
performed to determine LPA receptor expression.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Involvement of specific LPA receptor subtypes in LPA-induced migration. 
( A )                                      ( B )  
 
 
 
 
 
 
 
 
RASMCs were pretreated with the indicated concentrations of (A) DGPP (0-50 μM) (B) OMPT 
(0-50 μM) for 1 h. Cellular migration assays were then performed in the presence or absence of or 
LPA (10μM ). Values are means ±S.E.M n =3. *P＜0.01 vs. control (LPA alone). 
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2.4. P38MAPk Pathway Activation Is Required in LPA-Induced Migration 
 
We next wanted to further elucidate the molecular cascades involved in LPA-induced migration of 
RASMCs. Cells were treated with (0- 25 μM) LPA for 10 min and Western blot analysis performed to 
determine the activation of specific kinase signaling pathways using specific antibodies to detect the 
phosphorylated forms of p38MAPKand ERK. LPA induced an increase in the phosphorylation of p38 
MAPK and ERK in a dose-dependent manner, which reached peak at 10 μM LPA, approximately 
2-fold above the basal level, and then decreased (Figure 4). We next examined the effects of DGPP on 
the activity of ERKand p38MAPK. RASMCs were pretreated with DGPP (50 μM) for 30 min and then 
stimulated with 10 μM LPA for 10 min. The phosphorylation of ERK and p38MAPK were completely 
blocked by pretreatment with DGPP (Figure 5). To investigate the possible involvement of p38MAPK 
or ERK phosphorylation in LPA-induced RASMCs migration, we examined the effects of specific 
inhibitors for p38 MAPK and ERK kinases on cell migration. RASMCs were pretreated with a 
p38MAPK inhibitor, SB203580 (30 μM), and an ERK inhibitor, PD98059 (30 μM), for 30 min, and 
then stimulated with 10 μM LPA for 10 min. Cellular migration in response to LPA was analyzed. 
LPA-induced p38MAPK activation was attenuated to the base level by pretreatment with SB203580 
(Figure 6A). Migration assays show that a partial, but significant, reduction of migrated cells from 
91±6 (n =3) in the absence of SB203580 to 46 ±6 (n= 3) in the presence of SB203580 (Figure 6B). 
Pretreatment of the cells with PD98059 almost completely abolished the LPA-induced 
phosphorylation of ERK, but, in contrast to SB203580, it failed to block LPA-induced VSMC 
migration (Figures 6A and B).When SB203580 and PD98059 were coadministered,the inhibiting 
action of SB203580 on the RASMCs migration were not strengthened (Figure 6B). 
 
Figure 4. LPA induced phosphorylation of p38 MAPK and ERK. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Left panel) RASMCs were stimulated with the indicated concentrations of LPA for 10min. Total 
cell lysate was resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (Right 
panel) Densitometric quantification of MAPK phoshorylation. P38MAPK or ERK activation was 
determined as an increase in the ratio of phospho-MAPK/total MAPK. Values are means ±S.E.M n 
=3. *P＜0.01 vs. control (0μM LPA), ᇞP＜0.01 vs. each other group. Int. J. Mol. Sci. 2009, 10                 
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Figure 5. Effect of DGPP on p38 MAPK and ERK phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: (Left panel) RASMCs were pretreated with vehicle or DGPP (50μM) for 30 min, then 
stimulated with 10μM LPA or vehicle for 10 min. Total cell lysate was resolved by SDS-PAGE and 
immunoblotted with the indicated antibodies. (Right panel): Densitometric quantification of MAPK 
phoshorylation. P38MAPK or ERK activation was determined as an increase in the ratio of 
phospho-MAPK/total MAPK. Values are means ±S.E.M n =3. *P＜0.01 vs. control (LPA alone). 
 
Figure 6. Effects of p38 and ERK inhibition on LPA-induced migration of RASMCs. 
(A) 
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Figure 6. Cont. 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: (Left panel) RASMCs were pretreated with vehicle, SB203580 (30μM) or PD98059 (30μM) for 
30 min, then stimulated with 10 μM LPA or vehicle for 10 min. Total cell lysate was resolved by 
SDS-PAGE and immunoblotted with the indicated antibodies. (Right panel) Densitometric 
quantification of MAPK phoshorylation. P38MAPK or ERK activation was determined as an 
increase in the ratio of phospho-MAPK/total MAPK. *P＜0.01 vs. control (vehicle), ᇞP＜0.01 
vs.control (LPA alone). B: RASMCs were pretreated with SB203580or/and PD98059 then treated 
with 10 μM LPA. Cellular migration assays were performed. Values are means ±S.E.M n =3. *P＜
0.05 vs. control (LPA alone). 
 
2.5. Involvement of Gi Protein in LPA-Mediated Migration 
 
Three G-proteins have been previously shown to play a role in LPA signaling, Gi/o, Gq/11, and 
G12/13 [28,29]. LPA stimulates cell proliferation through activation of tyrosine kinase and MAP 
kinase, Gi/o-type proteins are the most likely candidates to mediate these effects [39].And results 
derived from LPA receptor knockout mice illustrate that at least in mouse embryonic fibroblasts 
(MEFs), LPA1 receptors is primarily coupled to Gi [28].So we employed PTX, a specific inhibitor of 
Gi/o to assess the role of G proteins in LPA-induced RASMCs migration. Overnight treatment 
(12h-14h) of the cells with PTX (100 ng/ml) prevented LPA-induced phosphorylation of p38 MAPK 
and ERK(Figure 7A) and almost completely abolished LPA-induced migration (Figure 7B). These 
data suggest that the Gi-activated pathways are upstream of p38 and ERK activation and required for 
LPA-induced RASMCs migration. 
LPA is released from activated platelets, injured cells, and growth factor-stimulated cells and has 
been shown to accumulate in the neointima of human atherosclerotic plaques [40]. It can also stimulate 
the proliferation [31] and migration [32] of VSMCs, thus it is considerably relevant to vascular disease, 
such as atherosclerosis [40,41] and vascular remodeling in vivo [32]. Although the effects of LPA have 
been widely studied, little is known about the role of LPA receptors and its signaling pathways 
activated by LPA in LPA-stimulated VSMCs migration. The present study shows that specific LPA 
receptor subtypes mediate LPA-induced migration in RASMCs through p38 MAPK activation.   Int. J. Mol. Sci. 2009, 10                 
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Figure 7. LPA induces RASMCs migration through Gi pathway. 
  (A) 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
RASMCs were pretreated overnight with 100 ng/mL PTX and then stimulated with 10 μM LPA or 
vehicle for 10 min. A: (Left panel) Total cell lysate was resolved by SDS-PAGE and immoblotted 
with the indicated antibodies. (Right panel) Densitometric quantification of ERK and p38 
phosphorylation. *P＜0.01 vs. control (LPA alone). B: RASMCs migration assay.*P＜0.01 vs. 
control (LPA alone). Values are means ±S.E.M n =3. 
 
A large body of evidence suggests that LPA induces cell migration in various cell lines [4-6,41]. In 
agreement with these results, we observed that LPA induces the migration of RASMCs in a 
dose-dependent manner.Furthermore, we found that the greatest number of migrating cells occurred at 
10 μM LPA and then dropped at higher dose. The reason for this may be that RASMCs were not sensitive 
or tolerant to the LPA stimulation at higher concentration of LPA. It is generally accepted that the 
diverse effects of LPA are mediated by its receptors. Receptor-mediated actions of LPA have 
important influences on cell survival, cytoskeletal remodeling, cell migration, and cell proliferation. In 
the present study, we demonstrate that RASMCs expressed two types of LPA receptor transcripts 
(LPA1 and LPA3) (Figure 2), and LPA-induced migration in RASMCs is mediated by specific LPA Int. J. Mol. Sci. 2009, 10                 
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receptors. Although both LPA1 and LPA3 are expressed, data suggests that LPA1, not LPA3, is 
required for LPA-induced RASMCs migration. Pretreatment of cells with an LPA1/LPA3-receptor 
antogonist, DGPP, prevented LPA-induced RASMCs migration. DGPP blocks LPA1 with a Ki of 6.6 
μM versus LPA3 with a Ki of 106 nM [36]. Lower concentrations of DGPP (0.1-1 μM), which inhibit 
only LPA3, were relatively ineffective at blocking cell migration. However, at concentrations more 
than 10 μM, which inhibit both LPA1 and LPA3, there was a significant reduction in RASMCs 
migration. This was further confirmed by data demonstrating that the LPA3 selective agonist, OMPT, 
hardly affected LPA-induced migration. However, since no specific LPA1 antagonist or agonist being 
available, this conclusion remains to be validated by further study with specific intervention on LPA1 
under our experimental conditions. 
LPA receptors couple to at least three G proteins including Gq, Gi, and G12/13, LPA1 and LPA2 
can couple to the Gi /o, G12/13, and Gq family, and LPA3 can couple to the Gi /o, and Gq family [42]. 
LPA induces various biological effects through these PTX-sensitive (Gi /o) or -insensitive (G12/13, 
Gq) G-proteins. The Hirshman and Emalan groups reported [43] that antisense oligonucleotide 
depletion of both Gqα and Gαi-2 proteins significantly inhibited LPA-induced actin reorganization in 
airway smooth muscle. These data indicate that LPA-induced actin reorganization, which is a 
fundamental process in cell motility and division, is mediated by both Gi and Gq pathways. In the 
present study, the migration response to LPA was completely inhibited by PTX treatment. This finding 
suggests that LPA acting via a receptor that couples to the Gi-protein to induce RASMCs migration. In 
contrast, Kim et al. [44] indicated that LPA coupling to Gq is the primary pathway that determines 
VSMCs migration and proliferation, however,they were also able to see some component of 
LPAGi-mediated signaling in the mouse VSMCs. This may be possibly due to the conditions for cell 
migration in vitro are very different, cells always interact with the matrix. The extracellular matrix 
might explain the discrepancy, while their assay used a Boyden chamber apparatus like our chemotaxis 
assays, the filters on which the cells migrated were coated with fibronectin. The underlying mechanism 
of the discrepant observations remains to be elucidated.   
Data from a variety of laboratories have indicated that several signal transduction molecules, 
including Src, phosphoinositide-3 kinase, and focal adhesion kinase, participate in the regulation of 
migration [45-47]. Mitogen-activated protein kinases (MAPKs), including p38 MAPK and ERK, have 
been shown to be activated downstream of GPCR. In addition, MAPKs have also been shown to be 
involved in regulating the migration and proliferation of VSMCs [35,36]. But there are conflicting 
views on which subfamily of MAPKs is involved in the intracellular signal pathway for cell migration. 
To check which signaling mechanism is involved in the regulation of LPA-induced RASMCs 
migration, we treated cells with different inhibitors. In the present study, LPA stimulated 
phosphorylation of p38 MAPK and ERK in RASMCs in a dose-dependent manner,which was in 
keeping with the migration assay . DGPP treatment completely abolished the LPA-induced p38MAPK 
and ERK activation, indicating that the LPA mediated the ERK and p38MAPK signaling pathways 
through LPA receptors.SB203580 treatment completely abolished the LPA-induced p38MAPK 
activation and, partially, but significantly, decreased migratory response to LPA. In contrast, although 
PD98059 treatment completely abolished LPA-induced ERK activation it did not influence 
LPA-induced migration. These data suggest a critical role for p38 MAPK, not ERK, in LPA induced 
RASMCs migration.  Int. J. Mol. Sci. 2009, 10                 
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A growing body of evidence suggests that p38 MAPK is involved in cell migration by remodeling 
the actin cytoskeleton [48,49]. P38MAPK acts as an upstream of the protein kinases that lead to the 
phosphorylation of Hsp27 in various types of cells. The activation of Hsp27 plays a key role 
inmodulating actin polymerization and the cytoskeletal remodeling associated with VSMCs migration 
in response to stimuli such as PDGF, IL-1β, TGF-β and sphingosine 1-phosphate [50,51]. In the 
present study, LPA stimulated phosphorylation of p38 and ERK in RASMCs, but the migration was 
only affect by p38MAPK inhibiter. Although in some studies, ERK activation has been described as a 
necessary event in VSMC migration, there are also studies citing no effect of ERK inhibition so as to 
our study, or even ERK-mediated inhibition of migration [52]. This may suggests that ERK kinase can, 
and probably does, participate in VSMC migration but that there is redundancy in the signaling 
networks that compensates for ERK inhibition. LPA-induced increase of p38 MAPK phosphorylation 
is also significantly inhibited by treatment with PTX, which demonstrates that activation of p38 
MAPK by LPA is mediated through Gi-protein activation.Further experiments are required to 
elucidate the interactions between Gi protein and p38 MAPK. 
The involvement of a small G protein Rho in migratory activity has also been extensively examined 
in the previous studies of vascular SMCs, but its role remains controversial [31,35,53,54]. Ai et al. 
reported that C3 toxin, a specific inhibitor of Rho, and Y-27632, a Rho kinase or ROCK inhibitor, 
have blocked vascular SMC migration induced by PDGF, and LPA, suggesting the positive 
involvement of Rho or Rho kinase in SMC migration [31]. However, some results of experiments also 
reported that Rho plays an inhibitory role in SMC migration [53,54]. The inhibitory role of Rho in cell 
migration has also been reported in other cell systems [55,56]. Further experiments are required to 
understand the role of intracellular signaling pathways, including the Rho signaling pathway, involved 
in the LPA receptor-mediated regulation of migration of SMCs. 
 
3. Conclusions 
 
We have demonstrated that LPA can stimulate RASMCs migration through the Gi-protein-coupled 
LPA1 receptor. LPA1-Gi-p38 signal cascade is important for VSMC migration in response to LPA. 
Inhibition of these pathways might be advantageous for controlling VSMCs migration associated with 
vascular diseases such as arteriosclerosis and restenosis. 
 
4. Experimental Section 
 
4.1. Materials 
 
1-Oleoyl-sn-glycero-3-phosphate (18:1LPA) and 1-oleoyl-2-O-methyl-rac-glycero-phospho- 
thionate (OMPT) were obtained from Sigma–Aldrich. Dioctylglycerol pyrophosphate (8:0) (DGPP 8:0) 
was from Avanti Polar Lipids. Pertussis toxin (PTX) was from Alexis Biochemicals Corporation. Anti- 
p38 mitogen-activated protein kinase (p38 MAPK), anti-phosphorylated p38 MAPK, anti- 
extracellular signal-regulated kinase (ERK), anti-phosphorylated ERK, SB203580 and PD98059 were 
from Santa Cruz Biotechnologies. 
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4.2. Cell Culture 
 
VSMCs were prepared from thoracic aorta of Sprague-Dawley rats, as previously described [57]. 
Subcultured cells from passages 3–5 were used and demonstrated 95% positive immunostaining with 
smooth muscle -actin antibody. For the experiments, VSMCs at 80–90% confluency were used after 
serum depletion with serum-free Dulbecco’s modified Eagle’s medium for 2–3 days. 
 
4.3. Determination of LPA Receptor Expression 
 
Total RNA was isolated from cultured VSMCs with Trizol according to the manufacturer’s protocol. 
RT-PCR was performed to determine the mRNA expression level of the LPA receptor subtypes (LPA1, 
LPA2, LPA3). Expression levels were normalized by GAPDH mRNA levels. The specific primer sets 
for rat LPA1, LPA2 and LPA3 were as follows: LPA1 Fwd 5′-GGAAGTATGTTTGTGGCTCTG–3′, 
Rev 5′–TTCTTGCGGAAGGTCAGG–3′, LPA2 Fwd 5′–TCAACACGGGACCTAATACC–3′, Rev 
5′–GGCGAACATAGCCAAAGAT–3′, and LPA3 Fwd 5′–CAGGGAGGGCAGTATGTT–3′, Rev 
5′–CCAGAATGGCTGTGAAGAT–3′. GAPDH primers used were Fwd 5′–ACCACAGTCCATGCCA 
TCAC–3′ and Rev 5′–TCCACCACCCTGTTGCTGTA–3′. 
 
4.4. Cell Migration Assay 
 
Cell migration was studied by the Boyden chamber method [58]. Briefly, test agents were placed in 
the lower chamber and an 8-μm polycarbonate filter was placed between the upper and lower 
chambers. Rat aortic smooth muscle cells (RASMCs) were trypsinized and resuspended at a 
concentration of 1x10
5 cells/mL in DMEM containing 0.5% bovine serum albumin (BSA) and 100 µL 
(1x10
5 cells) was added to the upper chamber. After incubation for 6 h at 37°C in a 5% CO2 incubator, 
filters were removed and the cells on the top surface of the membrane were removed with a cotton 
swab. The membranes were washed with phosphate-buffered saline, fixed with methanol and stained 
with hematoxylin and eosin. The number of cells that had migrated to the lower surface was 
determined by counting the cells in four randomly chosen places under a microscope at ×400 
magnification. The migration assay was performed in at least three independent experiments. 
 
4.5. Measurement of ERK and p38MAPK Activation 
 
To monitor ERK and p38 MAPK activation, SDS-PAGE was performed, followed by Western blot 
analysis with specific antibodies recognizing phospho-ERK, total ERK, and phospho-p38 MAPK, and 
total p38 MAPK following the manufacturer’s instructions. Briefly, treatment of RASMCs with 
various agents was terminated by addition of trichloroacetic acid, and the total cellular proteins were 
extracted with SDS-sample buffer [31]. An equal amount of protein (5 μg) was resolved by 
SDS-PAGE and transferred to Nitrocellulose Membrane (Pierce). To determine ERK and p38 MAPK 
phosphorylation, the membrane was incubated with each phosphospecific antibody. Immunoreactivity 
was visualized using an enhanced ECL detection kit (Pierce) and exposed to radiographic film. The 
blots were scanned and quantified by Gelpro32 (Beta 4.02 version for Windows). Int. J. Mol. Sci. 2009, 10                 
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4.6. Statistical Analysis 
 
Data were presented as mean ±S.E.M, statistical significance was determined by Student’s t-tests 
for comparisons between pairs of groups and by ANOVA for multiple comparisons. P<0.05 was 
considered to be statistically significant. 
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